Machine Learning for Predicting and Managing Quality of Life in Lung Cancer Immunotherapy Patients

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSecond Affiliated Hospital of Zunyi Medical University

About this trial

The goal of this study is to explore whether health-related quality of life (HRQoL) can be used as a predictive indicator for lung cancer patients and to implement clinical interventions. The study addresses two main objectives:

Analyzing HRQoL data of lung cancer patients undergoing immunotherapy using machine learning clustering methods to explore data patterns and build an HRQoL early warning model (already developed).

Validating this HRQoL early warning model in real-world settings by classifying patients with different HRQoL characteristics and assessing the clinical value of the model

Eligibility criteria

Qualifiers

Histologically diagnosed with lung cancer

Age over 18 years

Currently receiving immunotherapy for lung cancer

Good verbal communication ability

Disqualifiers

Cognitive impairment or mental illness

Other severe diseases

Trial design

Treatments tested in this trial

  • Symptom cluster-based care intervention
  • Conventional care intervention

Treatment groups

200 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Second Affiliated Hospital of Zunyi Medical University

Lead sponsor

Ministry of Education of the People's Republic of China, Department of Humanities and Social Sciences

Collaborator